In response to crackdowns on abortion rights in the US after Roe v. Wade was overturned, the Food and Drug Administration has changed risk evaluation and mitigation strategy (REMS) policies regarding Mifeprex, an abortion pill, that will increase patient access. The drug was formerly only available at registered clinics, but can now be dispensed at a pharmacy or by mail. It still requires a prescription, however, a potential barrier in many states.
According to Phil Taylor, “Mifeprex was first approved in 2000 as a combination regimen with misoprostol for ending pregnancy, with restrictions under a REMS to ensure its safe use, and generics entered the market in 2019. In 2021, the FDA reviewed the REMS programme for the drug, and said it may loosen the requirements to reduce burden on healthcare systems, assuming that the benefits of the product outweigh its risks. The updated REMS marks the culmination of that review.”
To read more, click here.
(Source: Pharmaphorum, January 4th, 2022)